Inventio Science

Senior-Led FSP for Early-Phase Clinical Development

Phase I–II programmes executed with precision, accountability, and regulatory rigour, across Europe, North America, APAC, and LATAM.

The problem we solve

Why Early-Phase Outsourcing Fails, and How We Fix It

Most FSP and CRO partnerships fail at the same predictable points: accountability blurs across functional handoffs, sponsor SOPs get interpreted rather than followed, and junior staff are left managing decisions that need senior judgement. Programmes slip. Data gaps appear. Inspections reveal what governance should have caught.

Inventio Science is built around a different model, we keep experienced experts at the point of execution, not just the point of oversight.

Home / problem section
01

No layers

Every functional area is led by someone with 20+ years of hands-on experience in early-phase development.

02

Sponsor SOP execution

Not interpretation: we work to your quality standards, governance frameworks, and ways of working.

03

Transparent governance

Milestone status in real time, so course-correction happens before problems escalate.

04

Inspection-readiness

Documentation standards, audit trails, and data-quality controls are embedded from Day 1, not retrofitted before an inspection.

05

Senior continuity

Our cohesive, long-standing team means none of the disruption of CRO staff turnover.

Inventio Science’s FSP model combines senior scientific expertise with disciplined operational execution, so your Phase I–II programmes reach milestones reliably, your data is defensible, and your regulatory relationships stay intact.
What we deliver

Functional Service Provider Solutions for Biotechnology and Academic Drug Development

We run First-in-Human (FIH), dose-escalation, healthy-volunteer, and Phase I–II patient studies for biotech companies, academic sponsors, and CROs. Fixed-scope engagements or fully integrated FSP coverage, both models bring the same senior team to your programme.

Home quote band (full width)
“Senior people in the pitch. The same senior people in the trial.”
Duchesse Kala-Kala, Founder & CEO, Inventio Science
From molecule to Phase II

See how we support emerging biotech from nonclinical package to Phase II

One relationship. No gaps between preclinical and clinical. Smooth oversight from strategy to execution.

Home / preclinical link

What makes it work

  1. Senior-led teams with direct sponsor access
  2. Sponsor SOP execution, not interpretation
  3. Transparent programme governance
  4. Inspection-readiness built in
  5. Senior continuity, no handovers

Let’s talk about your programme

Whether you have a specific functional gap, a full Phase I programme to resource, or a question about our approach, the right starting point is a conversation.